Cargando…

Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention

Multiple myeloma (MM), a malignant neoplasm of plasma cells that reside in the bone marrow (BM), is universally preceded by a precursor state termed monoclonal gammopathy of undetermined significance (MGUS). Many individuals with MGUS never progress to MM or progress over many years. Therefore, MGUS...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCachren, Samuel S., Dhodapkar, Kavita M., Dhodapkar, Madhav V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952530/ https://www.ncbi.nlm.nih.gov/pubmed/33717170 http://dx.doi.org/10.3389/fimmu.2021.632564

Ejemplares similares

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
por: Costa, Federica, et al.
Publicado: (2018)

Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?
por: Dhodapkar, Madhav V., et al.
Publicado: (2019)

Role of Tissue-Resident Memory in Intra-Tumor Heterogeneity and Response to Immune Checkpoint Blockade
por: Dhodapkar, Kavita M.
Publicado: (2018)

Enhancement of clonogenicity of human multiple myeloma by dendritic cells
por: Kukreja, Anjli, et al.
Publicado: (2006)

SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer
por: Dhodapkar, Kavita M, et al.
Publicado: (2013)

Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells
por: Dhodapkar, Kavita M., et al.
Publicado: (2002)

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy
por: Robinson, M. Hope, et al.
Publicado: (2023)

A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma
por: Dhodapkar, Madhav V., et al.
Publicado: (2003)

Risk-associated alterations in marrow T cells in pediatric leukemia
por: Bailur, Jithendra Kini, et al.
Publicado: (2020)

Natural Killer T Cells in Cancer Immunotherapy
por: Nair, Shiny, et al.
Publicado: (2017)

Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity
por: Moreno, Alberto, et al.
Publicado: (2023)

Tissue resident memory T cells create genetically distinct immune microenvironments within melanoma metastasis
por: Dhodapkar, Kavita, et al.
Publicado: (2015)

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma
por: Nooka, Ajay K., et al.
Publicado: (2022)

Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches
por: Paiardini, Mirko, et al.
Publicado: (2020)

Game of Bones: How Myeloma Manipulates Its Microenvironment
por: Moser-Katz, Tyler, et al.
Publicado: (2021)

Therapeutic strategies to enhance immune response induced by multiple myeloma cells
por: Liu, Zhaoyun, et al.
Publicado: (2023)

A survey-wide association study to identify youth-specific correlates of major depressive episodes
por: Dhodapkar, Rahul Madhav
Publicado: (2020)

Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
por: Dhodapkar, Kavita M., et al.
Publicado: (2007)

Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
por: Dhodapkar, Kavita M., et al.
Publicado: (2007)

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
por: Dhodapkar, Kavita, et al.
Publicado: (2014)

The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma
por: Brevi, Arianna, et al.
Publicado: (2022)

Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients
por: Zhaoyun, Liu, et al.
Publicado: (2021)

Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
por: Branagan, Andrew R., et al.
Publicado: (2021)

Immune Defects in the Risk of Infection and Response to Vaccination in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
por: Tete, Sarah M., et al.
Publicado: (2014)

Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
por: Yao, Lijun, et al.
Publicado: (2022)

Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy
por: Dhodapkar, Madhav V., et al.
Publicado: (2003)

Delivery-Corrected Imaging of Fluorescently-Labeled Glucose Reveals Distinct Metabolic Phenotypes in Murine Breast Cancer
por: Frees, Amy E., et al.
Publicado: (2014)

Co-evolution of tumor and immune cells during progression of multiple myeloma
por: Liu, Ruiyang, et al.
Publicado: (2021)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

Editorial: Evolution of Innate Immunity in Eukarya: Advances and Implications
por: Scholz, Jean L., et al.
Publicado: (2022)

Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma
por: Pilcher, William, et al.
Publicado: (2023)

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
por: Jagannath, Sundar, et al.
Publicado: (2018)

Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma
por: Mansour, Anna, et al.
Publicado: (2017)

Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment
por: Lopes, Raquel, et al.
Publicado: (2022)

Molecular and immunological mechanisms of clonal evolution in multiple myeloma
por: Forster, Stefan, et al.
Publicado: (2023)

Evolution of Two Major Zika Virus Lineages: Implications for Pathology, Immune Response, and Vaccine Development
por: Beaver, Jacob T., et al.
Publicado: (2018)

Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
por: Pittari, Gianfranco, et al.
Publicado: (2017)

Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune Profiling
por: Teh, Benjamin W., et al.
Publicado: (2017)

The Role of the Crosstalk Between Gut Microbiota and Immune Cells in the Pathogenesis and Treatment of Multiple Myeloma
por: Jasiński, Marcin, et al.
Publicado: (2022)

The yin–yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma
por: Yi, Zhigang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fgfpd3eds2408dpr9b10pqj2i1